NIH statement on preliminary efficacy results of twice-yearly lenacapavir for HIV prevention in cisgender women
2024-06-26
(Press-News.org) The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor. Lenacapavir is administered every six months, making it the most durable HIV prevention method to have shown efficacy in this population. NIAID applauds the study sponsor, investigators, study staff, and—most importantly—the participants in South Africa and Uganda, for contributing to this scientific advance for cisgender women, a population for whom biomedical HIV prevention evidence has been limited to date. We look forward to the release of additional data from this pivotal study, as well as the outcomes of companion studies of lenacapavir in other populations, to inform regulatory decisions on this novel PrEP method.
The Phase 3 findings build on decades of discovery and translational research and collaboration between public and private sector to steer promising concepts from the laboratory to the clinic. The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and its grantees have collaborated with Gilead scientists to provide instrumental evidence on the structure of HIV, contributing to the development of lenacapavir. NIAID-funded scientists continue to study the activity of lenacapavir in the body, characterize resistance to lenacapavir’s drug class, and work to develop a method for analyzing lenacapavir drug levels, among other efforts. This research will inform future drug development and clinical research. In addition, the NIH-funded HIV Prevention Trials Network is implementing two Gilead-sponsored studies in the United States of lenacapavir in cisgender women and people who inject drugs. NIAID is coordinating with Gilead and other partners to consider the implications, if any, of the Phase 3 findings for ongoing studies in similar populations.
Long-acting PrEP formulations are an important option for people who experience barriers to daily pill-taking, and a twice-annual injection could dramatically improve the feasibility of PrEP for many people who stand to benefit from its use. Long-acting cabotegravir, administered once every two months, already is used in the United States and is increasingly available in low- and middle-income countries. The controlled-release monthly dapivirine vaginal ring is approved for HIV PrEP in cisgender women in several African countries. Equitable access is essential for realizing the benefits of long-acting PrEP, particularly in geographic areas and among populations experiencing steady or increasing HIV incidence. We continue to learn more about all forms of PrEP and new information helps public health agencies and services reach the people who stand to benefit most from PrEP with safe and effective options that best meet their needs.
For more information about these studies, please visit ClinicalTrials.gov using the identifiers NCT04994509, NCT06101329 and NCT06101342.
Media inquiries can be directed to the NIAID Office of Communications at 301-402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-06-26
The City University of New York has appointed Joshua C. Brumberg as president of the CUNY Graduate Center, making permanent a post he has held on an interim basis since October 2023. Brumberg, a neurobiologist who has been a faculty member, dean and researcher during his 22-year career at CUNY, will lead the University’s renowned center of graduate education, scholarship and public-interest research. CUNY’s Board of Trustees approved the appointment at its meeting last night.
“Dr. Brumberg has played a key role in expanding CUNY’s research enterprise over the past several years,” said Chancellor Félix V. Matos Rodríguez. “A ...
2024-06-26
Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours—sometimes more than a day—in a reversible intermediate state, according to a discovery by researchers at Weill Cornell Medicine. Their revelation of this fundamental feature of biology includes details of its mechanisms and dynamics, which may inform the development of future therapies targeting cancers and other diseases.
In their study, published June 26 in Nature, the researchers developed new tools allowing them to track over time the activation state of E2F, a ...
2024-06-26
ST. LOUIS, MO, June 26, 2024 – With the goal of reducing the time and cost it takes to bring an improved crop to the marketplace, research conducted in the laboratory of Keith Slotkin, PhD, and his colleagues in the Plant Transformation Facility at the Donald Danforth Plant Science Center, was recently published in the scientific journal Nature. The publication Transposase-assisted target site integration for efficient plant genome engineering focuses on technology called TATSI (Transposase-Assisted Target Site Integration), which uses transposable elements to integrate custom DNA into specific sites in plant genomes.
The ...
2024-06-26
Bacteria populate virtually every habitat on Earth, including within and on our own bodies. Understanding and engineering bacteria can lead to new methods for diagnosing, treating, and preventing infections. Additionally, it presents opportunities to protect crops from disease and create sustainable cell factories for chemical production, reducing environmental impact — just a few of the many benefits to society. To unlock these advantages, scientists need the ability to manipulate the genetic content of these bacteria. However, a longstanding bottleneck in genetically engineering bacteria has been the efficient ...
2024-06-26
The U.S. Department of Energy’s (DOE) Argonne National Laboratory will support three innovative artificial intelligence (AI)-driven science projects as part of the first round of awards from the National Artificial Intelligence Research Resource (NAIRR) Pilot.
Led by the National Science Foundation (NSF) in collaboration with DOE and several partners, the NAIRR Pilot aims to provide researchers and students with expanded access to key AI resources and data. NAIRR’s ultimate goal ...
2024-06-26
“We wanted to investigate how second pillar pension funds react to financial crises and how to protect them from the crises,” says Kaunas University of Technology (KTU) professor Dr Audrius Kabašinskas, who, together with his team, discovered a way to achieve this goal. The discovery in question is the development of stress tests for pension funds. Lithuanian researchers were the first in the world to come up with such an adaptation of the stress tests.
Stress tests are usually carried out on banks or other financial institutions to allow market regulators to determine and assess their ability to withstand adverse economic conditions.
According to the professor at ...
2024-06-26
About The Study: Multivitamin use was not associated with a mortality benefit in this cohort study of U.S. adults. Still, many adults report using multivitamins to maintain or improve health.
Corresponding Author: To contact the corresponding author, Erikka Loftfield, Ph.D., M.P.H., email erikka.loftfield@nih.gov.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.18729)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, ...
2024-06-26
In order to convert sunlight into electricity or other forms of energy as efficiently as possible, the very first step is an efficient light-harvesting system. Ideally, this should be panchromatic, i.e. absorb the entire spectrum of visible light.
The light-collecting antennae of plants and bacteria are a model for this. They capture a broad spectrum of light for photosynthesis, but are very complex in structure and require many different dyes to transmit the energy of the absorbed light and focus it on a central point.
The light-harvesting systems developed by humans to date also have disadvantages:
Although ...
2024-06-26
Neuroscientists have discovered how the brain bidirectionally controls sensitivity to threats to initiate and complete escape behaviour in mice. These findings could help unlock new directions for discovering therapies for anxiety and post-traumatic stress disorder (PTSD).
The study, published today in Current Biology, outlines how researchers at the Sainsbury Wellcome Centre at UCL studied a region of the brain called the periaqueductal gray (PAG), which is known to be hyperactive in people with anxiety and PTSD. Their ...
2024-06-26
Transgender women are still at risk for prostate cancer. A new study led by Cedars-Sinai Cancer investigators, published in the peer-reviewed Journal of the American Medical Association, concludes that current screening guidelines could miss early-stage prostate cancer in transgender women on hormone therapy.
The prostate, a small gland that helps make semen, also produces a protein called prostate-specific antigen, or PSA. Blood levels of PSA tend to be elevated in people who have prostate cancer, and the PSA test, which measures those levels, is a common prostate ...
LAST 30 PRESS RELEASES:
[Press-News.org] NIH statement on preliminary efficacy results of twice-yearly lenacapavir for HIV prevention in cisgender women
